Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16809121 | 0.85 | TSHR (0.40) | SMN1; SMN2TSHR | |
| SCHEMBL5987579 | 0.80 | TSHR (0.46) | SMN1; SMN2CA14CA12TSHRALDH1A1 | |
| SCHEMBL16805836 | 0.80 | TSHR (0.35) | SMN1; SMN2CA14CA12TSHR | |
| SCHEMBL7604349 | 0.80 | TSHR (0.46) | SMN1; SMN2CA14CA12TSHRALDH1A1 | |
| SCHEMBL5987835 | 0.80 | TSHR (0.46) | SMN1; SMN2CA14CA12TSHRALDH1A1 | |
| SCHEMBL10709224 | 0.80 | ALDH1A1 (0.41) | SMN1; SMN2CA14TSHRALDH1A1 | |
| SCHEMBL16809122 | 0.80 | ALDH1A1 (0.48) | SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL9625694 | 0.79 | TSHR (0.50) | SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL12390072 | 0.77 | SMN1; SMN2 (0.36) | SMN1; SMN2CA14CA12TSHR | |
| SCHEMBL16732019 | 0.77 | ALDH1A1 (0.33) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150166520-A1 | AMIDO-SUBSTITUTED PYRIMIDINONE DERIVATIVES USEFUL FOR THE TREATMENT OF HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166520-A1 | AMIDO-SUBSTITUTED PYRIMIDINONE DERIVATIVES USEFUL FOR THE TREATMENT OF HIV INFECTION | ARG1, ASS1, ARG2 | SMN1; SMN2 2816/4885CA14 4873/4885CA12 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.